{"schema":"sb.node.v1","id":"sb:e/e20001c47e40d4b109d5f837","kind":"entity","label":{"text":"immunotherapy","locale":"en"},"identity":{"anchor":"label:en:immunotherapy","strength":"label"},"asOf":{"knowledgeCutoff":"2026-11-10T23:26:12.528504+00:00","releaseId":"sb-8792b91ece33","snapshot":"deploy cb03188cd71ab9aaafd7516efad4097bf188509c"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":912,"separatePublishers":180,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.465,"named":424,"of":912,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)","blind":["only 47% of the 912 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","kind":"legacy","kindBasis":"seed","reason":"entity graph provenance 'curated'; part of the hand-written seed vocabulary that predates machine promotion; no receipt exists","policy":"promotion (seed vocabulary; no receipt)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-11","to":"2026-11-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","share":0.053,"blind":["5% of mentions say something specific about it; the rest only name it"]}},"dimensions":{"domains":["oncology","pubmed_targeted"],"activeDays":158,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/6598a9e8293e1f4187ed1cc1","kind":"observation","label":"Korea Times News · 2026-11-09 · Samsung Bioepis' Keytruda biosimilar demonstrates equivalence in global Phase 3 trial","url":"https://www.koreatimes.co.kr/business/companies/20261109/samsung-bioepis-keytruda-biosimilar-demonstrates-equivalence-in-global-phase-3-trial?utm_source=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/ba32b01b4f8342dc229c8756","kind":"observation","label":"Frontiers Precision Oncology · 2026-11-09 · Granzyme B as a predictive biomarker for therapeutic outcomes in non-small cell lung cancer patients undergoing anti-PD-1 therapy","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1964690","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/880312c5bc7c2a455da8b7d8","kind":"observation","label":"24/7 Wall St. · 2026-11-08 · Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Ot…","url":"https://247wallst.com/personal-finance/2026/11/08/two-70-year-olds-will-start-the-same-12272-keytruda-qlex-cancer-injections-one-with-medigap-plan-g-will-owe-0-in-coinsurance-after-the-part-b-deductible-while-the-other-will-owe-20-with-no-annual/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/d24b0a7e43809897de49b09d","kind":"observation","label":"Seoul Economic Daily · 2026-11-08 · Samsung Bioepis Says Keytruda Biosimilar Matches Original in Phase 3","url":"https://en.sedaily.com/finance/2026/11/08/samsung-bioepis-says-keytruda-biosimilar-matches-original","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/977d45f44adc2e4d7d7578a4","kind":"observation","label":"BIOENGINEER.ORG · 2026-11-08 · AI biomarkers show promise for predicting cancer immunotherapy response, review finds","url":"https://bioengineer.org/ai-biomarkers-show-promise-for-predicting-cancer-immunotherapy-response-review-finds/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/d4614554c45bd2b5c705dd92","kind":"observation","label":"Tech Times · 2026-11-07 · Samsung Bioepis Puts Keytruda Biosimilar Into FDA Review With Full Phase 3 Lung Cancer Trial Data","url":"https://www.techtimes.com/articles/330213/20261106/samsung-bioepis-puts-keytruda-biosimilar-fda-review-full-phase-3-lung-cancer-trial-data.htm","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/f772251e8d269fd7e3f8adff","kind":"observation","label":"Nature Reviews Clinical Oncology · 2026-11-06 · Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC","url":"https://www.nature.com/articles/s41571-026-01232-0","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/75c531e3b1a494175393f410","kind":"observation","label":"European Medical Journal · 2026-11-06 · Assessing Immunotherapy Response in Gastrointestinal Cancers","url":"https://www.emjreviews.com/oncology/podcasts/assessing-immunotherapy-response-in-gastrointestinal-cancers/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/b65ace4b7783f6e6de26968f","kind":"observation","label":"The Lancet Oncology Online First · 2026-11-05 · [Comment] Co-targeting angiogenesis and immune checkpoints in breast cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00526-7/fulltext?rss=yes","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/0e35afd0aae5de181a07838f","kind":"observation","label":"J Immunother Cancer · 2026-11-05 · Steering the immune response: cancer vaccines and the next era of cancer immunotherapy.","url":"https://doi.org/10.1136/jitc-2026-017100","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTExLTEwVDIzOjI2OjEyLjUyODUwNCswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":11,"byKind":{"claim":1,"co-mentioned":10},"items":[{"id":"sb:p/9622e5755e4f615c88249cf5","kind":"claim","label":"Samsung Bioepis Puts Keytruda Biosimilar Into FDA Review With Full Phase 3 Lung Cancer Trial Data — corroborated","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with colorectal cancer (384 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0725cc3ec034d8655a343f00"},{"kind":"relation","label":"co-mentioned with fda (195 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7452689d97c7c885406e799d"},{"kind":"relation","label":"co-mentioned with lung cancer (193 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/27c8d6ca13365be381edf726"},{"kind":"relation","label":"co-mentioned with clinical trial (145 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9484f7f975002eb0509f095e"},{"kind":"relation","label":"co-mentioned with china (138 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb9e3f039eba6f25b268eee0"},{"kind":"relation","label":"co-mentioned with t-cell (127 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/90bb905c886825b7846113cc"},{"kind":"relation","label":"co-mentioned with clinical trials (127 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/116372fb08f0a4f060f8498e"},{"kind":"relation","label":"co-mentioned with ai (122 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b4153e66ecd99644a79e3a27"},{"kind":"relation","label":"co-mentioned with merck (118 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e7bd02adf1bffa8ec3cf2f01"}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMS0xMFQyMzoyNjoxMi41Mjg1MDQrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/e20001c47e40d4b109d5f837","mcp":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}","page":"/entity/immunotherapy/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}